EBMT 2024 | Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias

Patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) continue to have a poor prognosis, meaning the development of novel strategies to treat these patients is crucial. Anthony Stein, MD, City of Hope, Duarte, CA, discusses the potential of a novel approach, total marrow and lymphoid irradiation (TMLI), for treating poor-risk acute leukemias. This targeted form of radiation exposes the skeletal system where the leukemia resides to the maximum radiation dose while significantly reducing the dose of radiation received by healthy organs. In a study at the City of Hope, TMLI was combined with cyclophosphamide and etoposide in patients with intermediate- to high-risk AML and ALL. At 2 years, the overall survival (OS) and progression-free survival (PFS) are significantly higher than those traditionally seen with other treatment regimens. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.